DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Kantarjian H, Thomas D, Jorgensen J et al.
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Lancet Oncol 2012;
13: 403-411
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.